About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.

Increasing DR Screening Through TOP: Supporting Implementation and Identifying Opportunities for Scale up in Ontario

Clinicaltrials.gov identifier NCT03927859

Recruitment Status Recruiting

First Posted April 25, 2019

Last update posted April 25, 2019

Study Description

Brief summary:

It is recommended that people with diabetes have their eyes screened for retinopathy every 1-2 years. Retinopathy can lead to visual impairment and blindness, but early detection through regular retinal screening can help to prevent this. Many Ontarians with diabetes have not been receiving regular screening. One possible way to get more people screened for retinopathy involves tele-retinal screening using teleophthalmology (TOP), where patients can have their eyes screened in their local clinic or a site nearby. In this project, we are testing 3 patient interventions: mailing a letter, phone call or an option to bundle their screening with other diabetic care services (e.g. foot care exam) and examine the impact of these various interventions alone or in combination with each other.

  • Condition or Disease:Diabetes Mellitus, Type 2
    Diabetes Mellitus, Type 1
  • Intervention/Treatment: Other: a mail letter, a phone call and a phone call plus mailed letter
  • Phase: N/A
Detailed Description

Currently in Ontario, about a third of patients with diabetes, or more than 400,000 individuals, have not had their screening done within the last two years. The rates are even lower if you examine screening rates within the last year. Within Ontario, the highest rates of unscreened individuals live in the Greater Toronto Area (Toronto Central Local Health Integration Network (LHIN), Central LHIN and Central West LHIN). Despite the recommendation for patients to be screened every year, currently only about 5% of patients in TCLHIN and CLHIN have been screened within the last year based on a preparatory analysis for this study. It is, therefore, important to identify which intervention strategies, or combination of strategies, will be most effective in improving screening rates in Ontario. While many studies have examined the effects of various strategies individually, for this project we aim to use several interventions that have been identified in the past as being effective and examine the effects of these interventions alone or in combination. The approach we are taking in this study is the Multiphase Optimization Strategy (MOST). This study design approach consists of three stages: a screening phase, a refining phase and a confirming phase. During the screening phase, several intervention approaches are evaluated alone or in combination with each other in order to assess which intervention(s) have the greatest potential for impact on the selected outcome. During the refining phase of MOST, the selected components are fine-tuned and issues such as optimal levels of each component are investigated. During the confirming phase, the selected components are delivered at optimal levels and the intervention showing greatest promise is evaluated through a standard randomized controlled trial.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 420 participants
  • Allocation: Randomized
  • Intervention Model: Factorial Assignment
  • Intervention Model Description: This is a Multiphase Optimization Strategy (MOST) trial. All patients will be randomized to one of 4 (or 3 for one of the sites) intervention conditions in a fractional factorial design.
  • Masking: None (Open Label) ()
  • Primary Purpose: Supportive Care
  • Official Title: Increasing Diabetic Retinopathy Screening Through the Teleophthalmology Program (TOP): Supporting Implementation and Identifying Opportunities for Scale up in Ontario
  • Actual Study Start Date: July 2018
  • Estimated Primary Completion Date: June 2019
  • Estimated Study Completion Date: August 2019
Arms and interventions
Arm Intervention/treatment
Active Comparator: Mail + Phone call
Patients assigned to this arm will first have letters mailed out to them (identical to the ones mailed out in the letter only arm). A week later, the letter will be followed up by a phone call as per the phone only arm. Patients will be asked if they have already booked, and if not, will be provided with information about the program as per the phone call script in the phone only arm.
Other: a mail letter, a phone call and a phone call plus mailed letter
All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present. Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention.
Active Comparator: Mailing Letter
Patients assigned to this arm, in which a letter is mailed out will receive 2 pamphlets in the mail. One pamphlet described the teleophthalmology program and the other pamphlet was designed by the Canadian Association of Ophthalmologists and describes what DR is and why screening is important. The letter will also contain contact information about the closest TOP to the area of the PCP practice.
Other: a mail letter, a phone call and a phone call plus mailed letter
All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present. Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention.
Active Comparator: Phone call
Administrative staff on site of each practice will contact all patients assigned to this arm by a phone call. The patient will be informed that they are calling from the family health practice that the patient belongs to. The reason for the call will be that the patient has been identified as somebody who is likely overdue for a screening test. Patients will be asked if they have had a screening test done recently, and if not, they will be offered an appointment. Patients that refuse an appointment, will be politely probed for reasons and attempts will be made to provide them with information on potential solutions to these barriers (e.g. patients working 9-5 on weekdays will be informed that they can access TOP on evenings). The call will also be used as an opportunity to inform patients about the importance of screening.Three attempts will be made to reach each patient. Only a single voicemail message will be left, when the possibility is available.
Other: a mail letter, a phone call and a phone call plus mailed letter
All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present. Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention.
Outcome Measures
  • Primary Outcome Measures: 1. Number of bookings made through the TOP program [ Time Frame: 1 year ]
    The primary outcome for the study is the number of bookings made through the TOP program
  • Secondary Outcome Measures: 1. Number of self-reported booking made outside of TOP [ Time Frame: 1 year ]
    Secondary outcomes include the number of self-reported booking made outside of TOP
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

Only patients diagnosed with Type I or Type II Diabetes with no evidence in their medical
records of a screening within the last 2 years will be included in the study and only
individuals 18 years of age or older will be included.

Exclusion Criteria:

Patients screened within the last year. In addition, individuals who cannot speak English
will be excluded from the study to minimize additional workload placed on administrative
staff.

Contacts and Locations
Contacts

Contact: Vess Stamenova, PhD 416-323-6400 ext 5112 vess.stamenova@wchospital.ca

Contact: Nike Onabajo, MSc 4163236400 ext 5126 nike.onabajo@wchospital.ca

Locations

Canada, Ontario
Black Creek Community Health Centre
Toronto

Canada, Ontario
Women's College Hospital Family Health Team
Toronto

Sponsors and Collaborators

Women's College Hospital

Canadian Institutes of Health Research (CIHR)

Diabetes Action Canada

Investigators

Principal Investigator: Michael H Brent, MD, FRCSC University Health Network, Toronto Western Hospital

Principal Investigator: Onil Bhattacharyya, MD, PhD Women's College Hospital

Principal Investigator: Laura Desveaux, PhD Women's College Hospital

Principal Investigator: Vess Stamenova, PhD Women's College Hospital

More Information
  • Responsible Party: Women's College Hospital
  • ClinicalTrials.gov Identifier: NCT03927859 History of Changes
  • Other Study ID Numbers: 2018-0068-E
  • First Posted: April 25, 2019 Key Record Dates
  • Last Update Posted: April 25, 2019
  • Last Verified: April 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Diabetes Mellitus
    Diabetes Mellitus, Type 2
    Diabetes Mellitus, Type 1